The content on this site is intended for healthcare professionals only
Prof Bernard Escudier (Institut Gustave-Roussy, Paris, France), Dr Nizar Tannir (University of Texas M.D. Anderson Cancer Center, Houston, USA), and Dr David Cella (Northwestern University, Chicago, USA) discuss the efficacy, tolerability and quality of life issues surrounding metastatic renal cell carcinoma (mRCC) at ESMO 2014 in Madrid.
From the same symposium:
Achieving efficacy beyond clinical trials
Are we doing all we can to manage adverse events?
Understanding the patient's perspective
GlaxoSmithKline fully provided for the costs of this symposium, honoraria for the chairs & speakers and provided input into the symposium agenda/content.
Gaza's cancer patients: Navigating the dual struggle of illness and war
Grand Rounds: Improving quality of patient-centred care
The Southeast Asian Breast Cancer Symposium; background, aims and successes
War in Ukraine: The Global Medical Knowledge Alliance's response to improving cancer care
The iCCaRE Consortium for Black Men - Addressing the disproportionate burden of prostate cancer
Management of prostate cancer in Africa: Looking to the future
Assessment of QoL results and correlation with survival outcomes in phase III clinical trials in metastatic NSCLC
Digital rectal examination is not useful as a solitary screening tool for prostate cancer in young men
Single intensive screening intervention using PSA and Stockholm3 in combination might reduce prostate cancer mortality
